FREELAND — Michigan remains one of the nation’s leading research centers for medical technologies. With this research comes opportunity for new business. The MidMichigan Innovation Center and BlueWater Angels along with the Office for Innovation at Covenant HealthCare will be co-hosting a health technology forum to showcase five new Michigan companies — each company having potential to dramatically impact the future of medicine.
One of the roles of the Covenant HealthCare Office for Innovation is to stay abreast of new technological developments and early stage companies that have promising futures in the health care space. The BlueWater Angels Investment Network, housed in the MidMichigan Innovation Center, provides funding for early stage companies throughout the Great Lakes Bay Region and across the state. Over the past four years, BlueWater Angels has been successful in finding, funding and supporting some exciting health care companies.
In support of these efforts, the partners will host a special “Health-Tech Forum.” Forum attendees will hear about the commercialization of breakthrough technologies in medical science that are emerging here, in Michigan.
The Health-Tech Forum takes place Wednesday, April 10 at Apple Mountain in Freeland from 5 to 8:30 p.m. with an opportunity to network with some of the state’s leading medical entrepreneurs. Ken Kousky, CEO of the MidMichigan Innovation Center and President of BlueWater Angels, will give a brief overview of angel and venture investing in Michigan’s health sciences. Kousky’s overview will be followed by presentations from five medical technology companies seeking growth capital.
Members of the community interested in learning more about these exciting health care technologies or angel investing are encouraged to attend this forum.
For more information about the BlueWater Angels, please contact Ken Kousky at (989) 482-9306. If the media wishes to speak with Terry Lerash, of the Covenant Office for Innovation, please contact Kristin Knoll (989) 583-7655.
Presenting companies include Armune Bioscience Inc., developing diagnostic testing for prostate cancer by utilizing the antibodies created by the immune system to detect early stage cancer; ProNai Therapeutics Inc., applying proprietary, nucleic acid-based DNA interference technology to develop novel therapeutic approaches for proliferative diseases; RetroSense Therapeutics, a developer of gene therapy that delivers algal light-sensitive gene/protein to retinal layers that are not natively light sensitive; GEMA diagnostics, developing non-invasive human oocyte and embryo selection methods to fundamentally improve the prospects for in vitro fertilization; and RealBio Technology Inc., developing a culture system designed to promote in vitro growth and maintenance of tissues that exhibit many key characteristics of normal in vivo tissue organization and function.